NASDAQ:PBYI Puma Biotechnology - PBYI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.21 -0.13 (-5.56%) (As of 03/23/2023 04:00 PM ET) Add Compare Share Share Today's Range$2.21▼$2.3850-Day Range$2.25▼$4.8252-Week Range$1.60▼$5.16Volume254,697 shsAverage Volume344,403 shsMarket Capitalization$103.08 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Puma Biotechnology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside262.0% Upside$8.00 Price TargetShort InterestHealthy2.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.25Based on 2 Articles This WeekInsider TradingSelling Shares$172,216 Sold Last QuarterProj. Earnings Growth100.00%From $0.19 to $0.38 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.61 out of 5 starsMedical Sector149th out of 986 stocksPharmaceutical Preparations Industry57th out of 477 stocks 3.5 Analyst's Opinion Consensus RatingPuma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Puma Biotechnology has a forecasted upside of 262.0% from its current price of $2.21.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.97% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Puma Biotechnology has recently increased by 2.68%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PBYI. Previous Next 2.1 News and Social Media Coverage News SentimentPuma Biotechnology has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Puma Biotechnology this week, compared to 1 article on an average week.Search Interest7 people have searched for PBYI on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows1 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $172,216.00 in company stock.Percentage Held by Insiders21.20% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.58% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Puma Biotechnology are expected to grow by 100.00% in the coming year, from $0.19 to $0.38 per share.Price to Earnings Growth RatioPuma Biotechnology has a PEG Ratio of 4.48. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Puma Biotechnology (NASDAQ:PBYI) StockPuma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.Read More Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comPuma Biotechnology (NASDAQ:PBYI) Lifted to Buy at StockNews.comMarch 6, 2023 | finance.yahoo.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2022 Earnings Call TranscriptMarch 23, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 3, 2023 | msn.comPuma stock slumps ~15% as Q4 sees loss on lawsuit settlement; impact on Nerlynx sales in Q1March 3, 2023 | finance.yahoo.comPuma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales TopMarch 1, 2023 | finance.yahoo.comPuma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care ConferenceFebruary 1, 2023 | finance.yahoo.comPuma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 MutationJanuary 25, 2023 | finance.yahoo.comPuma Biotechnology's (NASDAQ:PBYI) investors will be pleased with their decent 96% return over the last yearMarch 23, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. January 12, 2023 | finance.yahoo.comPuma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology ConferenceJanuary 12, 2023 | reuters.comPBYI.OQ - | Stock Price & Latest News | ReutersJanuary 9, 2023 | finance.yahoo.comPuma Biotechnology, Inc. (PBYI)December 20, 2022 | finance.yahoo.comInstitutional investors own a significant stake of 45% in Puma Biotechnology, Inc. (NASDAQ:PBYI)December 15, 2022 | finance.yahoo.comWhy Shares of Puma Biotechnology Rose This WeekDecember 1, 2022 | finance.yahoo.com15 Best Affordable Stocks Under $30November 22, 2022 | finance.yahoo.comIs Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?November 14, 2022 | finance.yahoo.comWhy Puma Biotech (PBYI) is a Top Momentum Stock for the Long-TermNovember 11, 2022 | ca.finance.yahoo.comPBYI vs. GMAB: Which Stock Should Value Investors Buy Now?November 9, 2022 | benzinga.comShort Volatility Alert: Puma Biotechnology, Inc.November 9, 2022 | finance.yahoo.comRegeneron (REGN) Gets FDA Nod for Libtayo's Label ExpansionNovember 9, 2022 | finance.yahoo.comPuma Biotechnology Third Quarter 2022 Earnings: Beats ExpectationsNovember 8, 2022 | finance.yahoo.comWhy Puma Biotechnology, Inc. (NASDAQ:PBYI) Looks Like A Quality CompanyNovember 4, 2022 | apnews.comPuma Biotechnology Reports Third Quarter 2022 Financial ResultsNovember 4, 2022 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Puma Biotechnology (PBYI)November 4, 2022 | finance.yahoo.comAgios (AGIO) Q3 Loss Narrower Than Expected, Sales MissNovember 4, 2022 | finance.yahoo.comIntra-Cellular (ITCI) Beat on Q3 Earnings and Sales EstimatesOctober 27, 2022 | finance.yahoo.comPuma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR SymposiumSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Company Calendar Last Earnings11/04/2021Today3/23/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PBYI CUSIPN/A CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees196Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+241.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio12.32 P/E Growth4.48Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio4.55 Current Ratio1.73 Quick Ratio1.67 Sales & Book Value Annual Sales$228 million Price / Sales0.48 Cash Flow$0.19 per share Price / Cash Flow12.64 Book Value$0.47 per share Price / Book4.98Miscellaneous Outstanding Shares46,640,000Free Float36,753,000Market Cap$109.14 million OptionableOptionable Beta1.03 Key ExecutivesAlan H. AuerbachChairman, President, CEO & SecretaryMaximo F. NouguesChief Financial & Accounting OfficerAlvin F. WongChief Scientific OfficerJeffrey LudwigChief Commercial OfficerMariann OhanesianSenior Director-Investor RelationsKey CompetitorsViveon Health AcquisitionNYSE:VHAQOpiant PharmaceuticalsNASDAQ:OPNTRVL PharmaceuticalsNASDAQ:RVLPTrevi TherapeuticsNASDAQ:TRVICapricor TherapeuticsNASDAQ:CAPRView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 49,760 shares on 2/15/2023Ownership: 0.109%Man Group plcBought 27,568 shares on 2/15/2023Ownership: 0.105%Jane Street Group LLCBought 40,818 shares on 2/15/2023Ownership: 0.089%Boothbay Fund Management LLCBought 20,218 shares on 2/15/2023Ownership: 0.044%Squarepoint Ops LLCBought 17,893 shares on 2/15/2023Ownership: 0.039%View All Insider TransactionsView All Institutional Transactions PBYI Stock - Frequently Asked Questions Should I buy or sell Puma Biotechnology stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PBYI shares. View PBYI analyst ratings or view top-rated stocks. What is Puma Biotechnology's stock price forecast for 2023? 1 brokers have issued 12-month price objectives for Puma Biotechnology's shares. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 241.9% from the stock's current price. View analysts price targets for PBYI or view top-rated stocks among Wall Street analysts. How have PBYI shares performed in 2023? Puma Biotechnology's stock was trading at $4.23 at the beginning of the year. Since then, PBYI shares have decreased by 44.7% and is now trading at $2.34. View the best growth stocks for 2023 here. When is Puma Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our PBYI earnings forecast. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.78. The biopharmaceutical company earned $46.20 million during the quarter, compared to analyst estimates of $53.44 million. The company's revenue for the quarter was down 9.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.79) EPS. What guidance has Puma Biotechnology issued on next quarter's earnings? Puma Biotechnology updated its first quarter 2023 earnings guidance on Thursday, March, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $47.00 million-$52.00 million, compared to the consensus revenue estimate of $51.00 million. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and What is Puma Biotechnology's stock symbol? Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI." Who are Puma Biotechnology's major shareholders? Puma Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (5.87%), Renaissance Technologies LLC (3.72%), Globeflex Capital L P (1.23%), Morgan Stanley (1.09%), Rice Hall James & Associates LLC (0.84%) and Geode Capital Management LLC (0.83%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Michael Patrick Miller, Richard Paul Bryce and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Puma Biotechnology's stock price today? One share of PBYI stock can currently be purchased for approximately $2.34. How much money does Puma Biotechnology make? Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $109.14 million and generates $228 million in revenue each year. How many employees does Puma Biotechnology have? The company employs 196 workers across the globe. How can I contact Puma Biotechnology? Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501. This page (NASDAQ:PBYI) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.